Lucid Diagnostics And Front Line Mobile Health Forge Partnership To Enhance Esophageal Cancer Screening Among First Responders

Author: Benzinga Newsdesk | September 03, 2024 07:57am

Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the execution of a memorandum of understanding (MOU) with Front Line Mobile Health ("Front Line"), a comprehensive medical care provider for first responders. The MOU focuses on the exploration of co-marketing and collaboration opportunities to promote and expand patient access to Lucid's EsoGuard® Esophageal DNA test for the early detection of esophageal precancer, particularly among firefighters. Lucid previously collaborated with Front Line to facilitate its first major directly-contracted #CheckYourFoodTube Precancer Testing Event.

Posted In: LUCD PAVM